EA201792116A1 - Ингибитор янус-киназы - Google Patents

Ингибитор янус-киназы

Info

Publication number
EA201792116A1
EA201792116A1 EA201792116A EA201792116A EA201792116A1 EA 201792116 A1 EA201792116 A1 EA 201792116A1 EA 201792116 A EA201792116 A EA 201792116A EA 201792116 A EA201792116 A EA 201792116A EA 201792116 A1 EA201792116 A1 EA 201792116A1
Authority
EA
Eurasian Patent Office
Prior art keywords
janus kinase
kinase inhibitor
proposed
janus
jak
Prior art date
Application number
EA201792116A
Other languages
English (en)
Other versions
EA036063B1 (ru
Inventor
Хао У
Вэйвэй Мао
Ицян Хуан
Лили Фань
Шухуэй Чэнь
Original Assignee
Уси Форчун Фармасьютикал Ко., Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уси Форчун Фармасьютикал Ко., Лтд filed Critical Уси Форчун Фармасьютикал Ко., Лтд
Publication of EA201792116A1 publication Critical patent/EA201792116A1/ru
Publication of EA036063B1 publication Critical patent/EA036063B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Предложен ряд ингибиторов Янус-киназы и, в частности, предложено соединение формулы (I) или его фармацевтически приемлемые соли, а также их применение для получения лекарственных средств для лечения заболеваний, связанных с Янус-киназой (JAK).
EA201792116A 2015-05-29 2016-05-26 Ингибитор янус-киназы EA036063B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510289933 2015-05-29
CN201610344370 2016-05-23
PCT/CN2016/083426 WO2016192563A1 (zh) 2015-05-29 2016-05-26 Janus激酶抑制剂

Publications (2)

Publication Number Publication Date
EA201792116A1 true EA201792116A1 (ru) 2018-07-31
EA036063B1 EA036063B1 (ru) 2020-09-22

Family

ID=57440054

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792116A EA036063B1 (ru) 2015-05-29 2016-05-26 Ингибитор янус-киназы

Country Status (17)

Country Link
US (1) US10174056B2 (ru)
EP (1) EP3305788B1 (ru)
JP (1) JP6564473B2 (ru)
KR (1) KR102081272B1 (ru)
CN (1) CN107531711B (ru)
AU (1) AU2016271904B2 (ru)
CA (1) CA2983481C (ru)
DK (1) DK3305788T3 (ru)
EA (1) EA036063B1 (ru)
ES (1) ES2822748T3 (ru)
HU (1) HUE050842T2 (ru)
MX (1) MX2017013797A (ru)
PL (1) PL3305788T3 (ru)
PT (1) PT3305788T (ru)
TW (1) TWI692481B (ru)
UA (1) UA118822C2 (ru)
WO (1) WO2016192563A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018095345A1 (zh) * 2016-11-23 2018-05-31 无锡福祈制药有限公司 一种7H-吡咯并[2,3-d]嘧啶类化合物的晶型、盐型及其制备方法
WO2019061299A1 (en) * 2017-09-29 2019-04-04 Rhodia Operations PROCESS FOR THE PREPARATION OF AMINOMETHYL-SUBSTITUTED HETEROCYCLOCCANE
CN107573364A (zh) * 2017-10-31 2018-01-12 无锡福祈制药有限公司 一种jak激酶抑制剂
CN107602590A (zh) * 2017-10-31 2018-01-19 无锡福祈制药有限公司 具有Janus激酶抑制活性的桥环化合物
CN107805259A (zh) * 2017-10-31 2018-03-16 无锡福祈制药有限公司 一种吡咯并嘧啶类化合物
CN107652308A (zh) * 2017-10-31 2018-02-02 无锡福祈制药有限公司 一种Janus激酶3抑制剂
CN107602591A (zh) * 2017-10-31 2018-01-19 无锡福祈制药有限公司 一种Janus激酶3抑制剂
CN107778321A (zh) * 2017-10-31 2018-03-09 无锡福祈制药有限公司 一种托法替尼类似物
AU2019426113B2 (en) * 2019-01-30 2022-06-16 Felicamed Biotechnology Co., Ltd. JAK inhibitor and preparation method therefor
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020288567B2 (en) * 2019-06-05 2023-06-15 Guangzhou Joyo Pharmatech Co., Ltd Pyrrolopyrimidine compound and use thereof
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN111004236B (zh) * 2019-12-19 2022-04-05 卓和药业集团股份有限公司 一种wxfl10203614中间体的动态动力学拆分方法
CN110923288A (zh) * 2019-12-19 2020-03-27 卓和药业集团有限公司 一种wxfl10203614中间体的生物学拆分方法
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
CN111087412B (zh) * 2019-12-31 2021-04-09 卓和药业集团有限公司 一类吡咯并嘧啶衍生物及其合成方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112168827A (zh) * 2020-11-03 2021-01-05 卓和药业集团有限公司 一种用于治疗银屑病的药物组合物及其制备方法
CN115124526B (zh) * 2020-12-04 2024-01-30 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物中间体及其制备方法
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
CN113372366B (zh) * 2020-12-04 2022-08-30 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的盐、其晶型及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102574A3 (en) * 1998-06-19 2002-01-28 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
JP4078074B2 (ja) * 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
YU42703A (sh) 2000-12-01 2006-03-03 Osi Pharmaceuticals Inc. Jedinjenja specifična za dobijanje adenozinske a1,a2a i a3 receptore i njihove primene
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
BRPI1007737A2 (pt) * 2009-04-20 2015-09-01 Auspex Pharmaceuticals Llc "composto da fórmula estrutural i, composição farmacêutica, método de tratamento de um distúbio mediano por janus quinase 3, método de preparação de um composto da fórmula estrutural ii, e método de preparação de um composto da fórmula estrutural xii"
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
CA2796388A1 (en) 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
AU2012323399A1 (en) 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
MX356401B (es) * 2011-12-12 2018-05-21 Dr Reddys Laboratories Ltd Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk).
EP2796460B1 (en) * 2011-12-21 2018-07-04 Jiangsu Hengrui Medicine Co. Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof
US8551542B1 (en) 2012-09-20 2013-10-08 Basic Research L.L.C. Methods and compositions for increasing growth hormones
LT3290421T (lt) * 2013-02-22 2019-02-25 Pfizer Inc. Pirolo [2, 3 -d]pirimidino darinių derinys su vienu arba daugiau papildomų agentų, kaip janus kinazės (jak) inhibitorių
BR112015020302B1 (pt) * 2013-02-27 2023-04-18 Mochida Pharmaceutical Co., Ltd Derivado de pirazol, composição farmacêutica e composto intermediário
HUE054560T2 (hu) * 2013-12-05 2021-09-28 Pfizer Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil és pirrolo[2,3-d]piridinil akrilamidok
ES2720066T3 (es) 2013-12-09 2019-07-17 Unichem Lab Ltd Mejora del proceso de preparación de (3R,4R)-(1-bencil-4-metilpiperidín-3-il)-metilamina
WO2015188369A1 (en) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Also Published As

Publication number Publication date
EP3305788A1 (en) 2018-04-11
MX2017013797A (es) 2018-03-21
JP2018516264A (ja) 2018-06-21
TWI692481B (zh) 2020-05-01
PL3305788T3 (pl) 2021-03-08
EP3305788A4 (en) 2018-11-07
HUE050842T2 (hu) 2021-01-28
AU2016271904B2 (en) 2018-05-10
KR20170141787A (ko) 2017-12-26
TW201706277A (zh) 2017-02-16
EA036063B1 (ru) 2020-09-22
US20180162879A1 (en) 2018-06-14
JP6564473B2 (ja) 2019-08-21
CN107531711A (zh) 2018-01-02
DK3305788T3 (da) 2020-09-28
AU2016271904A1 (en) 2017-11-09
US10174056B2 (en) 2019-01-08
CA2983481C (en) 2020-04-14
CA2983481A1 (en) 2016-12-08
CN107531711B (zh) 2020-03-31
EP3305788B1 (en) 2020-08-05
KR102081272B1 (ko) 2020-02-25
ES2822748T3 (es) 2021-05-04
UA118822C2 (uk) 2019-03-11
PT3305788T (pt) 2020-09-25
WO2016192563A1 (zh) 2016-12-08

Similar Documents

Publication Publication Date Title
EA201792116A1 (ru) Ингибитор янус-киназы
EA201791576A1 (ru) Ингибитор jak
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201792214A1 (ru) Соединения замещенного хиназолина
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
EA201490949A1 (ru) Ингибиторы киназ
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA201990833A1 (ru) Соединение пиридина
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201591339A1 (ru) Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
EA201692487A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
UA111382C2 (uk) Інгібітори протеїнкінази
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
AR103680A1 (es) Inhibidores selectivos de bace1
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
WO2016109217A3 (en) Btk inhibitors
EA201792689A1 (ru) Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.